INOVIO to Participate in Upcoming Scientific Conferences
INOVIO (NASDAQ: INO), a biotechnology company, has announced its participation in multiple upcoming scientific conferences to present data on its lead product candidate INO-3107 for Recurrent Respiratory Papillomatosis (RRP) and next-generation DNA medicine technology.
The company has initiated a rolling Biologics License Application (BLA) submission for INO-3107, with plans to complete the submission in H2 2025 and targeting FDA file acceptance by year-end. The presentations will take place across various conferences including the American Academy of Otolaryngology Annual Meeting, World Vaccine Congress Europe, and ESMO Congress.
Additionally, INOVIO will present the first preclinical data on DNA-encoded protein technology (DPROT) for Hemophilia A and showcase developments in DNA-encoded monoclonal antibody (DMAb) technology.
INOVIO (NASDAQ: INO), una società di biotecnologie, ha annunciato la sua partecipazione a diverse prossime conferenze scientifiche per presentare dati sul suo candidato lead INO-3107 per la Recurrent Respiratory Papillomatosis (RRP) e sulla tecnologia di medicina a DNA di nuova generazione. L'azienda ha avviato una presentazione rolling per la Biologics License Application (BLA) per INO-3107, con l’obiettivo di completare la presentazione nella seconda metà del 2025 e puntare all'accettazione della FDA entro la fine dell'anno. Le presentazioni si terranno in diverse conferenze, tra cui l'American Academy of Otolaryngology Annual Meeting, World Vaccine Congress Europe e l'ESMO Congress. Inoltre, INOVIO presenterà i primi dati preclinici sulla tecnologia proteica codificata da DNA (DPROT) per l'emofilia A e mostrerà gli sviluppi nella tecnologia degli anticorpi monoclonali codificati da DNA (DMAb).
INOVIO (NASDAQ: INO), una empresa de biotecnología, ha anunciado su participación en varias conferencias científicas próximas para presentar datos sobre su candidato principal INO-3107 para la Papilomatosis Respiratoria Recurrente (RRP) y sobre la tecnología de medicina de ADN de nueva generación. La compañía ha iniciado una presentación continua para la Biologics License Application (BLA) de INO-3107, con planes de completar la presentación en la segunda mitad de 2025 y apuntar a la aceptación del archivo por la FDA para fin de año. Las presentaciones se realizarán en conferencias como la American Academy of Otolaryngology Annual Meeting, World Vaccine Congress Europe y el ESMO Congress. Además, INOVIO presentará los primeros datos preclínicos sobre la tecnología de proteína codificada por ADN (DPROT) para la Hemofilia A y mostrará avances en la tecnología de anticuerpos monoclonales codificados por ADN (DMAb).
INOVIO (NASDAQ: INO), 생명공학 회사는 주력 후보 물질 INO-3107를 재발성 호흡기 유두종증(RRP)에 대해 발표하고 차세대 DNA 의약 기술을 공개하기 위해 다가오는 여러 과학 학회에 참여할 것이라고 발표했습니다. 회사는 INO-3107의 BLA 제출을 롤링 방식으로 시작했으며, 2025년 하반기에 제출을 완료하고 연말까지 FDA 접수를 목표로 하고 있습니다. 발표는 American Academy of Otolaryngology 연차총회, World Vaccine Congress Europe, ESMO Congress 등 다양한 학회에서 진행될 예정입니다. 또한 INOVIO는 DNA 인코딩 단백질 기술(DPROT)로 치료하는 혈우병 A에 대한 초기 비임상 데이터를 발표하고 DNA 인코딩 단일클론 항체(DMAb) 기술의 개발도 선보일 예정입니다.
INOVIO (NASDAQ: INO), une société de biotechnologie, a annoncé sa participation à plusieurs conférences scientifiques à venir pour présenter des données sur son candidat principal INO-3107 pour la récurrence de papillomatoses respiratoires (RRP) et sur la technologie médicale à ADN de nouvelle génération. L'entreprise a lancé une soumission BLA (Biologics License Application) pour INO-3107, avec pour objectif de terminer la soumission au cours du deuxième semestre 2025 et viser l'acceptation du dossier par la FDA d'ici la fin de l'année. Les présentations auront lieu lors de diverses conférences, notamment l'American Academy of Otolaryngology Annual Meeting, le World Vaccine Congress Europe et le ESMO Congress. De plus, INOVIO présentera les premiers résultats précliniques sur la technologie protéique codée par ADN (DPROT) pour l'hémophilie A et mettra en avant les avancées de la technologie des anticorps monoclonaux codés par ADN (DMAb).
INOVIO (NASDAQ: INO), ein Biotechnologieunternehmen, hat seine Teilnahme an mehreren bevorstehenden wissenschaftlichen Konferenzen angekündigt, um Daten zu seinem führenden Kandidaten INO-3107 bei wiederkehrender respiratorischer Papillomatose (RRP) und zur Technologie der DNA-Medizin der nächsten Generation zu präsentieren. Das Unternehmen hat eine rollierende Einreichung für die Biologics License Application (BLA) für INO-3107 eingeleitet, mit dem Ziel, die Einreichung im 2. Halbjahr 2025 abzuschließen und eine FDA-Annahme bis Jahresende anzustreben. Die Präsentationen finden auf verschiedenen Konferenzen statt, darunter die American Academy of Otolaryngology Annual Meeting, World Vaccine Congress Europe und der ESMO Congress. Zusätzlich wird INOVIO die ersten präklinischen Daten zur DNA-kodierten Protein-Technologie (DPROT) für Hämophilie A vorstellen und Entwicklungen in der DNA-kodierten Monoklonal-Antikörper-Technologie (DMAb) zeigen.
INOVIO (NASDAQ: INO)، شركة التكنولوجيا الحيوية، أعلنت عن مشاركتها في عدة مؤتمرات علمية مقبلة لعرض بيانات حول مرشحها الرئيسي INO-3107 لمرض الورم الحبيبي الرئوي المتكرر (RRP) وتقنية دواء DNA من الجيل الجديد. بدأت الشركة بتقديم طلب ترخيص المستحضرات البيولوجية (BLA) لـ INO-3107 بنظام التقديم المتسلسل، مع خطط لإكمال التقديم في النصف الثاني من 2025 واستهداف قبول الملف من قِبل FDA بنهاية السنة. ستعقد العروض في مؤتمرات مختلفة بما في ذلك اجتماع الجمعية الأمريكية لعلوم الأنف والأذن والحنجرة، World Vaccine Congress Europe، وESMO Congress. بالإضافة إلى ذلك، ستقدم INOVIO أول بيانات قبل السريرية عن تقنية البروتين المشفّر بالـDNA (DPROT) لعلاج الهيموفيليا A وتعرض التقدم في تقنية الأجسام المضادّة وحيدة النسيلة المشفّرة بالـDNA (DMAb).
INOVIO（NASDAQ: INO），一家生物技术公司，宣布将参与多场即将举办的科学大会，展示其领先候选药物 INO-3107 在复发性呼吸道乳头状瘤病（RRP）中的数据，以及下一代 DNA 药物技术。公司已启动 INO-3107 的生物制品许可申请（BLA）滚动提交，计划在 2025 年下半年完成提交，并力争在年末前获得 FDA 的受理。相关演讲将在多场会议上进行，包括美国耳鼻喉科医学会年会、欧洲世界疫苗大会和 ESMO 大会。此外，INOVIO 将展示 DNA 编码蛋白质技术（DPROT）在血友病 A 的前临床数据，并展示 DNA 编码单克隆抗体（DMAb）技术的进展。
- None.
- None.
- Several presentations to highlight key aspects of lead product candidate, INO-3107, as a potential treatment for Recurrent Respiratory Papillomatosis (RRP)
- Additional presentations focus on promise of next-generation DNA medicine technology, including the first preclinical data describing potential for DNA-encoded protein technology (DPROT) to address Hemophilia A
INOVIO also plans to highlight its next-generation DNA-medicine technology, including presentations on a Phase 1 clinical trial of a DNA-encoded monoclonal antibody (DMAb) product candidate and new preclinical data on DPROTs addressing Hemophilia A.
Presentations on INO-3107 for RRP:
American Academy of Otolaryngology – Head and Neck Surgery Annual Meeting
Date: October 11-13
Poster Title: DNA Immunotherapy (INO-3107) Demonstrates a Durable Response for Treatment of HPV-6/11 Recurrent Respiratory Papillomatosis
World Vaccine Congress Europe
Date: October 13
Time: 3:45 PM CEST
Presentation Title: Leveraging the Potential of DNA Immunotherapy: Long-Term Efficacy in HPV-6 & 11 Recurrent Respiratory Papillomatosis
European Society For Medical Oncology Congress
Date: October 19
Poster Title: DNA Immunotherapy (INO-3107) in HPV-6 & 11 Recurrent Respiratory Papillomatosis – Long-Term Efficacy
37th Annual International Papillomavirus Society Conference
Date: October 24
Time: 2:40 - 2:55 PM ICT
Presentation Title: Clinical Response to INO-3107 in RRP is Irrespective of Papilloma Microenvironment and Molecular Subtype
Date: October 25
Time: 6:54 - 7:00 PM ICT
E-Poster Title: DNA Immunotherapy (INO-3107) Induces Persistent Immune Responses Resulting in Long-term Efficacy Through Post-Treatment Year 2 for HPV 6&11 RRP
International Society for Vaccines Annual Congress
Stellenbosch, SA
Date: October 30
Time: 10:20 - 10:35 AM SAST
Presentation Title: Immunotherapy, INO-3107, is Well-Tolerated, Effective, and Elicits an Antigen-Specific T-cell Response in Adults with HPV-6 & 11 Recurrent Respiratory Papillomatosis
Presentations on Next-Generation DNA Medicine:
European Society of Gene and Cell Therapy Congress
Date: October 7-10
Poster Title: Employment of the CELLECTRA® in vivo gene delivery platform in a first in human (FIH) DNA encoded monoclonal antibody (DMAb) clinical trial
World Vaccine Congress Europe
Date: October 16
Time: 1:00 PM CET
Presentation Title: DMAb Technology: Next Generation DNA Medicine Design and Delivery
World Orphan Drug Congress
Date: October 29
Time: 11:10 AM CET
Presentation Title: DMAb Technology: The Transformational Potential of Next Gen DNA Medicine in Rare Disease
14th World Federation of Hemophilia Global Forum
Date: November 14
Time: 1:45 PM EST
Presentation Title: Novel FVIII Secretion Via Non-Viral Vector DNA Medicine Platform
Available abstracts will be shared on INOVIO's website following presentations.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.
Contacts
Media: Jennie Willson, (267) 429-8567, communications@inovio.com
Investors: Peter Vozzo - ICR Healthcare, (443) 213-0505, investor.relations@inovio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-to-participate-in-upcoming-scientific-conferences-302566500.html
SOURCE INOVIO Pharmaceuticals, Inc.
FAQ
When will INOVIO complete the BLA submission for INO-3107?
What conferences will INOVIO present at regarding INO-3107?
What is INO-3107 being developed to treat?
What new technology will INOVIO present data on for Hemophilia A?
